within Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J07A_BacterialVaccines.J07AM52_TetanusToxoidCombination;

model TetanusToxoidCombination
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C(
    weight = 70,
    F = 1,
    Cl = 5.555555555555556e-08,
    adminDuration = 600,
    adminMass = 500 / 1000000,
    adminCount = 1,
    Vd = 0.005,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>TetanusToxoidCombinationsWithTetanusImmunoglobulin</td></tr><tr><td>ATC code:</td><td>J07AM52</td></tr><td>route:</td><td>intramuscular</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>500</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>5.0</td><td>L</td></tr>
    <tr><td>clearance:</td><td>0.2</td><td>L/hour</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>A combination product containing tetanus toxoid, a vaccine used to induce active immunity against tetanus, together with tetanus immunoglobulin, which provides passive immediate immunity to tetanus. It is typically used for post-exposure prophylaxis in individuals with risk of tetanus infection, especially when immunization status is uncertain or incomplete. Both components are approved and widely used for prevention of tetanus.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for healthy adults; no direct pharmacokinetic studies or publications were found for the combination product.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.J.J07AM52 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end TetanusToxoidCombination;
